#netter2 ผลการค้นหา
5. #NETTER2: Lu-Dotatate vs SSA in 1L for advanced well differentiated Neuroendocrine tumors. - Significant PFS improvement (22.8mos vs 8.5mos, HR: 0.276) - “TTD in QoL remained similar b/w arms”????!!! - Is this new SoC? Accessibility and AEs is still a real concern. 6/7
NETTER-2 shows PRRT gives huge PFS benefit over octreotide on first line treatment of Neuroendocrine disease (HR 0.26) Is this PFS data practice changing for you ? #GI24
El próximo 19 de febrero hablaremos de los resultados del estudio #NETTER2 desde la perspectiva de Oncología y Medicina Nuclear. Os esperamos‼️ Link registro👇🏻 us06web.zoom.us/meeting/regist…
🔍Preplanned subgroup analysis of the #netter2 showed excellent results for all groups (pan, small intestine, grade 2 and 3) @myESMO #ESMOGI24
📣 New data from #NETTER2 at #ENETS24 🔊 Investigators are as accurate as central review, and waterfall plots are amazing!! Practice changing and new options for more aggressive NET patients 💪🏼 @GrupoGetne @VHIO @Netespana @vallhebron
Not all #NETs are equal - insights from #NETTER2 at #ESMO24 👉🏻 prognosis & response depend on 🔑 factors ✅Origin - small bowel > pancreas ✅Lower Ki67 ✅High SSTR uptake ❌NOT disease spread Full work-up & specialized assessment crucial to personalize treatment plans 🦓
#NETTER2 presented again at #ENETS24 🚨Practice changing results👇🏻 and hopefully lots to come in this space
🚨PRRT 1st line benefits in G2-3 advanced GEP-NETs - NETTER2 #GI24 ⬆️PFS by >12m median (vs SSA)👉🏻supports PRRT 1st line in G2-3 💥Unprecedented response rate: 43%👉🏻time for neoadj trial? 🤷🏻♀️G2-3 not bad with SSA: median PFS 8m & 9% ORR 👏🏻to team & PI Dr Singh @Sunnybrook!
#Subgroup analysis on #NETTER2 with #PRRT vs high dose SSA in #highKi67 #NETs CONFIRMS activity in 👉G2 and G3 👉Pancreas and SmallBowel 📝Lowest ORR in SmallBowel 👍🏻Short time to response ‼️Patient selection (not chemo pts) @myESMO @GrupoGetne #ESMOGI24 #ESMOAmbassadors
⭐Research highlight: The #NETTER2 trial establishes #radioligand therapy as a new first-line treatment for patients with high-grade, advanced gastroenteropancreatic neuroendocrine tumors — for whom evidence-based treatments are lacking. @TheLancet nature.com/articles/d4159…
Great thread and interesting POV 👏🏼 CAPTEM continues to be a feasible option in pNET g2-3 with higher disease burden… With the #NETTER2 results, what do you think of #MGMT status in 1L selection, CAPTEM vs PRRT⁉️ #GI24 @ASCO
Comments on my personal top 4 #GI24 abstracts (1/4): 1. NETTER-2 177Lu-DOTATATE vs high dose octreotide as 1L treatment of G2 or G3 GEP-NET (Ki67 between 10% and 55%): ⬆️ PFS (22.5 vs 8.5 mo, HR 0.27) ⬆️ ORR (43% vs 9%) I did not expect such good numbers. @OncoAlert 1/
Also really happy to see results on #NETTER2 trial using #prrt #theranostics #lutetium77 for grade2&3 patients with #pancreaticcancer #nets #neuroendocrinecancer #GI24 @netcanceraware @ASCO
Is NETTER-2 a practice-changing trial? Hot off the press, commentary from @cives_mauro and Jon Strosberg @MoffittNews. #netter2 #neuroendocrine #prrt nature.com/articles/s4157…
Fantastic review. Initial read of #Netter2 super impressive but raises further questions about clinical impact vs operational rate limiting barriers for RLT therapies facing providers in multiple solid tumors.
Subgroup analysis on NETTER2 - @DrAngelaLamarca @myESMO @GrupoGetne #Cancer #ESMOGI24 #NETTER2 #OncoDaily #Oncology oncodaily.com/92969.html
#NETTER2 interview with Simron Singh, MD can be seen @oncologytube here: bit.ly/3Sbz14H
Positive results from #netter2 trial, using PRRT in grade 2/ 3 #NeuroendocrineTumor shorturl.at/qtKSY
Not all #NETs are equal - insights from #NETTER2 at #ESMO24 👉🏻 prognosis & response depend on 🔑 factors ✅Origin - small bowel > pancreas ✅Lower Ki67 ✅High SSTR uptake ❌NOT disease spread Full work-up & specialized assessment crucial to personalize treatment plans 🦓
Is NETTER-2 a practice-changing trial? Hot off the press, commentary from @cives_mauro and Jon Strosberg @MoffittNews. #netter2 #neuroendocrine #prrt nature.com/articles/s4157…
Subgroup analysis on NETTER2 - @DrAngelaLamarca @myESMO @GrupoGetne #Cancer #ESMOGI24 #NETTER2 #OncoDaily #Oncology oncodaily.com/92969.html
⭐Research highlight: The #NETTER2 trial establishes #radioligand therapy as a new first-line treatment for patients with high-grade, advanced gastroenteropancreatic neuroendocrine tumors — for whom evidence-based treatments are lacking. @TheLancet nature.com/articles/d4159…
🔍Preplanned subgroup analysis of the #netter2 showed excellent results for all groups (pan, small intestine, grade 2 and 3) @myESMO #ESMOGI24
#Subgroup analysis on #NETTER2 with #PRRT vs high dose SSA in #highKi67 #NETs CONFIRMS activity in 👉G2 and G3 👉Pancreas and SmallBowel 📝Lowest ORR in SmallBowel 👍🏻Short time to response ‼️Patient selection (not chemo pts) @myESMO @GrupoGetne #ESMOGI24 #ESMOAmbassadors
#NETTER2 presented again at #ENETS24 🚨Practice changing results👇🏻 and hopefully lots to come in this space
🚨PRRT 1st line benefits in G2-3 advanced GEP-NETs - NETTER2 #GI24 ⬆️PFS by >12m median (vs SSA)👉🏻supports PRRT 1st line in G2-3 💥Unprecedented response rate: 43%👉🏻time for neoadj trial? 🤷🏻♀️G2-3 not bad with SSA: median PFS 8m & 9% ORR 👏🏻to team & PI Dr Singh @Sunnybrook!
📣 New data from #NETTER2 at #ENETS24 🔊 Investigators are as accurate as central review, and waterfall plots are amazing!! Practice changing and new options for more aggressive NET patients 💪🏼 @GrupoGetne @VHIO @Netespana @vallhebron
El próximo 19 de febrero hablaremos de los resultados del estudio #NETTER2 desde la perspectiva de Oncología y Medicina Nuclear. Os esperamos‼️ Link registro👇🏻 us06web.zoom.us/meeting/regist…
Fantastic review. Initial read of #Netter2 super impressive but raises further questions about clinical impact vs operational rate limiting barriers for RLT therapies facing providers in multiple solid tumors.
#NETTER2 interview with Simron Singh, MD can be seen @oncologytube here: bit.ly/3Sbz14H
Positive results from #netter2 trial, using PRRT in grade 2/ 3 #NeuroendocrineTumor shorturl.at/qtKSY
Great thread and interesting POV 👏🏼 CAPTEM continues to be a feasible option in pNET g2-3 with higher disease burden… With the #NETTER2 results, what do you think of #MGMT status in 1L selection, CAPTEM vs PRRT⁉️ #GI24 @ASCO
Comments on my personal top 4 #GI24 abstracts (1/4): 1. NETTER-2 177Lu-DOTATATE vs high dose octreotide as 1L treatment of G2 or G3 GEP-NET (Ki67 between 10% and 55%): ⬆️ PFS (22.5 vs 8.5 mo, HR 0.27) ⬆️ ORR (43% vs 9%) I did not expect such good numbers. @OncoAlert 1/
Also really happy to see results on #NETTER2 trial using #prrt #theranostics #lutetium77 for grade2&3 patients with #pancreaticcancer #nets #neuroendocrinecancer #GI24 @netcanceraware @ASCO
5. #NETTER2: Lu-Dotatate vs SSA in 1L for advanced well differentiated Neuroendocrine tumors. - Significant PFS improvement (22.8mos vs 8.5mos, HR: 0.276) - “TTD in QoL remained similar b/w arms”????!!! - Is this new SoC? Accessibility and AEs is still a real concern. 6/7
NETTER-2 shows PRRT gives huge PFS benefit over octreotide on first line treatment of Neuroendocrine disease (HR 0.26) Is this PFS data practice changing for you ? #GI24
5. #NETTER2: Lu-Dotatate vs SSA in 1L for advanced well differentiated Neuroendocrine tumors. - Significant PFS improvement (22.8mos vs 8.5mos, HR: 0.276) - “TTD in QoL remained similar b/w arms”????!!! - Is this new SoC? Accessibility and AEs is still a real concern. 6/7
NETTER-2 shows PRRT gives huge PFS benefit over octreotide on first line treatment of Neuroendocrine disease (HR 0.26) Is this PFS data practice changing for you ? #GI24
El próximo 19 de febrero hablaremos de los resultados del estudio #NETTER2 desde la perspectiva de Oncología y Medicina Nuclear. Os esperamos‼️ Link registro👇🏻 us06web.zoom.us/meeting/regist…
#Subgroup analysis on #NETTER2 with #PRRT vs high dose SSA in #highKi67 #NETs CONFIRMS activity in 👉G2 and G3 👉Pancreas and SmallBowel 📝Lowest ORR in SmallBowel 👍🏻Short time to response ‼️Patient selection (not chemo pts) @myESMO @GrupoGetne #ESMOGI24 #ESMOAmbassadors
Not all #NETs are equal - insights from #NETTER2 at #ESMO24 👉🏻 prognosis & response depend on 🔑 factors ✅Origin - small bowel > pancreas ✅Lower Ki67 ✅High SSTR uptake ❌NOT disease spread Full work-up & specialized assessment crucial to personalize treatment plans 🦓
#NETTER2 presented again at #ENETS24 🚨Practice changing results👇🏻 and hopefully lots to come in this space
🚨PRRT 1st line benefits in G2-3 advanced GEP-NETs - NETTER2 #GI24 ⬆️PFS by >12m median (vs SSA)👉🏻supports PRRT 1st line in G2-3 💥Unprecedented response rate: 43%👉🏻time for neoadj trial? 🤷🏻♀️G2-3 not bad with SSA: median PFS 8m & 9% ORR 👏🏻to team & PI Dr Singh @Sunnybrook!
📣 New data from #NETTER2 at #ENETS24 🔊 Investigators are as accurate as central review, and waterfall plots are amazing!! Practice changing and new options for more aggressive NET patients 💪🏼 @GrupoGetne @VHIO @Netespana @vallhebron
🔍Preplanned subgroup analysis of the #netter2 showed excellent results for all groups (pan, small intestine, grade 2 and 3) @myESMO #ESMOGI24
Also really happy to see results on #NETTER2 trial using #prrt #theranostics #lutetium77 for grade2&3 patients with #pancreaticcancer #nets #neuroendocrinecancer #GI24 @netcanceraware @ASCO
Something went wrong.
Something went wrong.
United States Trends
- 1. #DWTS 40.9K posts
- 2. Whitney 13K posts
- 3. Giannis 15K posts
- 4. Brunson 5,950 posts
- 5. Elaine 42.9K posts
- 6. Sixers 20.8K posts
- 7. #RHOSLC 5,386 posts
- 8. Alix 5,601 posts
- 9. Andy 65.2K posts
- 10. #WWENXT 15.9K posts
- 11. Ryan Rollins 1,361 posts
- 12. Kuzma 1,112 posts
- 13. Markstrom N/A
- 14. Flyers 8,783 posts
- 15. Don Lemon 8,856 posts
- 16. CJ McCollum N/A
- 17. Bucks 24.3K posts
- 18. Caden 6,095 posts
- 19. Josh Hart 1,202 posts
- 20. Sabonis 1,792 posts